JohnPeterSeibylMD

Nuclear Medicine • New Haven, CT

Molecular Neuroimaging, LLC

Join to view full profile

Dr. Seibyl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Seibyl's full profile

Already have an account?

Office
60 Temple St
Ste 8B
New Haven, CT 06510
Phone+1 203-401-4300

Education & Training

Yale-New Haven Medical CenterResidency, Nuclear Medicine, 1992 - 1994
Yale-New Haven Medical CenterResidency, Psychiatry, 1986 - 1990
Greenwich Hospital/Yale UniversityResidency, Internal Medicine, 1985 - 1986
Case Western Reserve University School of MedicineClass of 1986

Certifications & Licensure

CT State Medical License 1988 - 2024
American Board of Nuclear Medicine Nuclear Medicine
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease Start of enrollment: 2005 Jan 01
Completed
Not Applicable
An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) Start of enrollment: 2004 Mar 01
Completed
Phase 2
Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects Start of enrollment: 2006 Apr 01
Completed
Phase 1
Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease Start of enrollment: 2006 Nov 01
Completed
Phase 2
Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients Start of enrollment: 2007 Jan 01
Terminated
Phase 1
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.
Roxane Dilcher, Stephan Wall, Mattes Groß, Sabrina Katzdobler, Olivia Wagemann
Alzheimer's & Dementia. 2024-10-01
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.
Tien Dam, Gennaro Pagano, Michael C Brumm, Caroline Gochanour, Kathleen L Poston
NPJ Parkinson's Disease. 2024-09-27
1 citations
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.
Tien Dam, Gennaro Pagano, Michael C Brumm, Caroline Gochanour, Kathleen L Poston
Medrxiv. 2024-09-10

Journal Articles

Assessment of 18f-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
John Seibyl, MD, JAMA Neurology

Press Mentions

CWRU Alumni Give $7.5 Million to Case Western Reserve University for Research into Parkinson’s, Alzheimer’s and Multiple SclerosisJune 7th, 2021